Skip to main content

#USA, New York State Department of Health Confirms First Locally Acquired Case of #Chikungunya in #NewYork State (DoH)

 


ALBANY, N.Y. (October 14, 2025) — The New York State Department of Health today announced that a case of locally acquired chikungunya has been confirmed in New York State. Laboratory testing at the Department's Wadsworth Center confirmed the case in Nassau County on Long Island. This marks the first locally acquired case of chikungunya reported in New York State. No locally acquired cases have been reported in the U.S. states and territories since 2019.

An investigation suggests that the individual likely contracted the virus following a bite from an infected mosquito. While the case is classified as locally acquired based on current information, the precise source of exposure is not known. The Aedes albopictus mosquito, known to transmit chikungunya, is present in parts of downstate New York. Local transmission can occur when an A. albopictus mosquito bites an infected traveler, becomes infected and bites another person. The disease cannot be spread directly from one person to another.

"Our Wadsworth Center has confirmed this test result, which is the first known case of locally acquired Chikungunya in New York State. Given the much colder nighttime temperatures, the current risk in New York is very low." State Health Commissioner Dr. James McDonald said. "We urge everyone to take simple precautions to protect themselves and their families from mosquito bites."

Chikungunya is a mosquito-borne disease most common in tropical and subtropical regions. Symptoms include fever and joint pain, headache, muscle pain, joint swelling, or rash. The illness is rarely fatal and most patients recover within a week, though some may experience persistent joint pain. People at higher risk for severe disease include newborns infected around the time of birth, adults aged 65 and older, and individuals with chronic conditions such as high blood pressure, diabetes or heart disease.

In 2025, there have been three additional chikungunya cases outside New York City that were all linked to international travel to regions with active chikungunya infections. Routine mosquito testing conducted by the Department's Wadsworth Center and the New York City Department of Health and Mental Hygiene (DOHMH) has not detected chikungunya virus in any New York mosquito samples to date.

Mosquito activity in New York is declining as cooler fall temperatures begin. The Department reminds all New Yorkers to take precautions to reduce the risk of mosquito bites:

-- Use EPA-registered insect repellents

-- Wear long sleeves, long pants and socks outdoors when possible

-- Remove standing water around homes, such as in flowerpots, buckets and gutters

-- Repair or patch holes in window and door screens to keep mosquitoes out

(...)

Source: Department of Health, https://www.health.ny.gov/press/releases/2025/2025-10-14_chikungunya.htm

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...